London, United Kingdom
President and CEO at IMMUNOCLIN CORPORATION (IMCL)
Biotechnology
Education
London School of Hygiene and Tropical Medicine, U. of London 1983 — 1989
PhD, Pharmacology and natural products
The School of Pharmacy, University of London 1982 — 1989
PhD, Pharmacology of natural products, chemical and biological characterization of novel molecules
Jagiellonian University 1974 — 1980
MSc, Biology and Neuropharmacology, 1st grade
Adam Mickiewicz Lyceum
II LO Im. A. Mickiewicza , Skarzysko- Kam.
II LO Im. A. Mickiewicza , Skarzysko- Kam.
II LO Im. A. Mickiewicza , Skarzysko- Kam.
Experience
Cannabis Science Inc. November 2014 - Present
Cannabis Science Inc. November 2014 - Present
IMMUNOCLIN CORPORATION (IMCL) December 2013 - Present
OMNICANNA Health Solutions May 2013 - Present
ImmunoClin Ltd 2002 - Present
University of London 2002 - Present
CANNABIS SCIENCE INC (CBIS) May 2013 - November 2014
The Medical Research Council Clinical Trials Unit 2004 - 2011
GlaxoSmithKline 1998 - 2002
Glaxo Wellcome Inc 1997 - 1999
Skills
Molecular Biology, Personalized Medicine, Biochemistry, Cell Biology, Medical Writing, Oncology, Virology, Immunoassays, Food Science, Infectious Diseases, Regulatory Affairs, Drug Development, Medicine, Product Development, Neuroscience, Biotechnology, Cancer, CRO, FDA, Hardware Diagnostics, Vaccines, Genomics, Business Development, Lifesciences, Pharmaceutics, Microbiology, Pharmacology, Cell, Pharmaceutical Industry, Biomarkers, Immunology, Commercialization, Translational Research, Bioinformatics, Science, Technology Transfer, Drug Discovery, Cell Culture, Medical Affairs, Protein Chemistry, Clinical Research, Clinical Trials, Medical Devices, GLP, DNA, Start-ups, In Vitro, Biopharmaceuticals, R&D, Clinical Development